Pulse Biosciences, Inc. (NASDAQ:PLSE - Get Free Report) crossed below its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of $17.79 and traded as low as $16.52. Pulse Biosciences shares last traded at $17.72, with a volume of 101,693 shares trading hands.
Analyst Ratings Changes
Separately, StockNews.com upgraded shares of Pulse Biosciences to a "sell" rating in a research note on Friday, September 20th.
View Our Latest Stock Analysis on PLSE
Pulse Biosciences Stock Performance
The firm has a fifty day moving average of $17.70 and a 200 day moving average of $14.22. The firm has a market capitalization of $1.06 billion, a PE ratio of -20.01 and a beta of 1.74.
Pulse Biosciences (NASDAQ:PLSE - Get Free Report) last announced its quarterly earnings data on Wednesday, October 30th. The company reported ($0.21) earnings per share (EPS) for the quarter. During the same quarter in the previous year, the business posted ($0.19) earnings per share.
Hedge Funds Weigh In On Pulse Biosciences
Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its stake in shares of Pulse Biosciences by 28.8% in the first quarter. Vanguard Group Inc. now owns 847,212 shares of the company's stock worth $7,379,000 after acquiring an additional 189,227 shares during the last quarter. Cetera Advisors LLC acquired a new position in Pulse Biosciences in the 1st quarter worth about $109,000. BNP Paribas Financial Markets raised its stake in shares of Pulse Biosciences by 63.6% during the 1st quarter. BNP Paribas Financial Markets now owns 7,597 shares of the company's stock worth $66,000 after purchasing an additional 2,952 shares in the last quarter. Price T Rowe Associates Inc. MD acquired a new stake in shares of Pulse Biosciences during the 1st quarter valued at about $88,000. Finally, Quest Partners LLC bought a new stake in shares of Pulse Biosciences in the 2nd quarter valued at approximately $91,000. Hedge funds and other institutional investors own 76.95% of the company's stock.
About Pulse Biosciences
(
Get Free Report)
Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.
Featured Articles
Before you consider Pulse Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulse Biosciences wasn't on the list.
While Pulse Biosciences currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
